Drug intelligence / Profile preview

puliginurad

Development stage: Unknown
Lead developer: Shanghai YingLi Pharmaceutical Co. Ltd.
Modality: Small Molecules
Administration: Oral

Overview

Puliginurad (YL-90148) is a potent and selective small molecule inhibitor of the urate transporter 1 (URAT1; SLC22A12), developed by Yingli Pharmaceutical. By inhibiting URAT1 in the kidneys, puliginurad prevents the reabsorption of uric acid from the renal tubules back into the bloodstream, thereby promoting uric acid excretion and reducing serum uric acid levels. It is currently being investigated in Phase 3 clinical trials for the treatment of gout and hyperuricemia, including asymptomatic hyperuricemia.

Other names: Puliginurad

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on puliginurad.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on puliginurad.

Explore the full profile